Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk SALT LAKE CITY, July 17, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from its nationwide Cancer Risk...